# A Phase II Trial of LM103 in Advanced Melanoma

Source: https://onco.cc/trials/nct07310784/  
OnCo record `nct07310784` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel in melanoma, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.

## Summary

A Phase II Trial of LM103 in Advanced Melanoma is a phase 2 interventional study registered as NCT07310784 by Suzhou BlueHorse Therapeutics Co., Ltd., with 92 participants planned, started 2025-12-16 and due to reach its primary completion in 2027-12-31. Interventions recorded: LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin. Conditions listed: Advanced Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07310784
- Phase: 2
- Setting: A Multicenter, Randomized, Controlled, Open-label, Phase II Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Treatment of Advanced Melanoma
- Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT07310784: https://clinicaltrials.gov/study/NCT07310784

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Dacarbazine](https://onco.cc/drugs/dacarbazine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct07310784.json